Oculis (NASDAQ:OCS) Receives Buy Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Oculis (NASDAQ:OCS) in a report released on Tuesday,Benzinga reports. Chardan Capital currently has a $28.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Monday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $28.80.

Oculis Stock Performance

Shares of Oculis stock opened at $18.22 on Tuesday. Oculis has a one year low of $10.50 and a one year high of $18.40. The company has a market capitalization of $737.98 million, a PE ratio of -9.44 and a beta of -0.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The company has a 50-day simple moving average of $16.35 and a two-hundred day simple moving average of $13.84.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.